Net loss significantly widened to $10,603,392 in 2025 from $2,379,092 in 2024. Revenues decreased by $126,048 to $461,452 in 2025, primarily due to customer transitions from fixed service agreements to time-and-materials in preparation for PET-CT upgrades. Cost of sales increased by $1,646,258 to $2,575,742 in 2025, driven by personnel, product testing, new product launch preparation, higher maintenance costs, and a $576,862 inventory write-down. General and administrative expenses surged by $6,521,144 to $8,384,173 in 2025, largely due to share-based payments ($4,982,588), expanded sales and marketing, and hardware/software upgrades. The company had an accumulated deficit of $144,937,079 as of December 31, 2025. Cash and cash equivalents increased to $2,520,466 at December 31, 2025, from $69,791 at December 31, 2024, supported by $10,000,000 from common stock sales. Management identified material weaknesses in disclosure controls and internal control over financial reporting, including inadequate segregation of duties and lack of multiple supervision levels. The company is pursuing FDA 510(k) clearance for its next-generation Affinity PET-CT 4D 64-slice system, which is currently undergoing safety and performance testing. All previously designated series of preferred stock were undesignated effective March 18, 2026, returning 36,750,000 shares to the authorized but unissued preferred stock pool.